Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-mercaptopurine study in relapsing acute myeloid leukemia
NL-OMON28582Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mercaptopurine in acute myeloid leukemia (AML), sponsored by University Medical Center Groningen. Primary endpoints: Expression of multidrug-resistance genes, nuclear receptors and in vitro susceptibility for 6-MP, Changes in the lymphoid compartment during treatment with 6-MP and 2 more. Started Jun 2008; status: recruiting.
02
Drugs
mercaptopurine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON28582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28582.